Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Numab AG
DescriptionAnti-CD3 antibody fragment activating T killer cells
Molecular Target CD23
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentDiscovery
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today